Request for Information (RFI): Inviting Comments and Suggestions on an ODS Strategic Plan 2025-2029: A Blueprint for a Coordinated Dietary Supplement Research Agenda at NIH, 54472-54473 [2024-14481]
Download as PDF
54472
Federal Register / Vol. 89, No. 126 / Monday, July 1, 2024 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
Final regulations (42 CFR part 5) were
published on November 17, 1980 (45 FR
75996) that include the criteria for
designating HPSAs. Criteria were
defined for seven health professional
types: primary medical care, dental,
psychiatric, vision care, podiatric,
pharmacy, and veterinary care. The
criteria for correctional facility HPSAs
were published on October 29, 1987 (52
FR 41594) and revised March 2, 1989
(54 FR 8735). The criteria for psychiatric
HPSAs were expanded to mental health
HPSAs on January 22, 1992 (57 FR
2473). Currently funded PHS Act
programs use the primary medical care,
mental health, or dental HPSA or
relevant sub-score designations such as
Maternity Care Target Areas.
HPSA designation offers access to
potential federal assistance. Public or
private nonprofit entities are eligible to
apply for assignment of National Health
Service Corps personnel to provide
primary medical care, mental health, or
dental health services in or to these
HPSAs. National Health Service Corps
health professionals enter into service
agreements to serve in federally
designated HPSAs. Entities with clinical
training sites located in HPSAs are
eligible to receive priority for certain
residency training program grants
administered by HRSA’s Bureau of
Health Workforce (BHW). Other federal
programs also utilize HPSA
designations. For example, under
authorities administered by the Centers
for Medicare & Medicaid Services,
certain qualified providers in
geographic area HPSAs are eligible for
increased levels of Medicare
reimbursement.
Content and Format of Lists
The three lists of designated HPSAs
are available on the HRSA Data
Warehouse shortage area topic web
page, including those proposed for
withdraw, and include a snapshot of all
geographic areas, population groups,
and facilities that were designated
HPSAs as of April 15, 2024. This notice
incorporates the most recent annual
reviews of designated HPSAs and
supersedes the HPSA lists published in
the Federal Register on January 2, 2024
(FR/Vol. 89, No. 1, Tuesday, January 2,
2024/Document Number 2023–28844).
The proposed for withdraw HPSAs will
remain in that status until the lists are
finalized this fall. States have the
opportunity to provide additional
information as part of the review of
proposed for withdraw HPSAs prior to
the lists being finalized this fall.
In addition, all Indian Tribes that
meet the definition of such Tribes in the
Indian Health Care Improvement Act of
VerDate Sep<11>2014
20:36 Jun 28, 2024
Jkt 262001
1976, 25 U.S.C. 1603, are automatically
designated as population groups with
primary medical care and dental health
professional shortages. Further, the
Health Care Safety Net Amendments of
2002 provides eligibility for automatic
facility HPSA designations for all
federally qualified health centers
(FQHCs) and rural health clinics that
offer services regardless of ability to
pay. Specifically, these entities include
FQHCs funded under section 330 of the
PHS Act, FQHC Look-Alikes, and Tribal
and urban Indian clinics operating
under the Indian Self-Determination
and Education Act of 1975 (25 U.S.C.
450) or the Indian Health Care
Improvement Act. Many, but not all, of
these entities are included on this
listing. Absence from this list does not
exclude them from HPSA designation;
facilities eligible for automatic
designation are included in the database
when they are identified.
Each list of designated HPSAs is
arranged by state. Within each state, the
list is presented by county. If only a
portion (or portions) of a county is (are)
designated, a county is part of a larger
designated service area, or a population
group residing in a county or a facility
located in the county has been
designated, the name of the service area,
population group, or facility involved is
listed under the county name. A county
that has a whole county geographic or
population group HPSA is indicated by
the phrase ‘‘County’’ following the
county name.
Development of the Designation and
Withdrawal Lists
Requests for designation or
withdrawal of a particular geographic
area, population group, or facility as a
HPSA are received continuously by
BHW. Under a Cooperative Agreement
between HRSA and the 54 state and
territorial Primary Care Offices (PCOs),
PCOs conduct needs assessments and
submit applications to HRSA to
designate areas as HPSAs. BHW refers
requests that come from other sources to
PCOs for review. In addition, interested
parties, including Governors, state
Primary Care Associations, and state
professional associations, are notified of
requests so that they may submit their
comments and recommendations.
BHW reviews each recommendation
for possible addition, continuation,
revision, or withdrawal. Following
review, BHW notifies the appropriate
agency, individuals, and interested
organizations of each designation of a
HPSA, rejection of recommendation for
HPSA designation, revision of a HPSA
designation, and/or advance notice of
pending withdrawals from the HPSA
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
list. Designations (or revisions of
designations) are effective as of the date
on the notification from BHW and are
updated daily on the HRSA Data
Warehouse website. The effective date
of a withdrawal will be the next
publication of a notice regarding the list
of designated HPSAs in the Federal
Register.
Carole Johnson,
Administrator.
[FR Doc. 2024–14477 Filed 6–28–24; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Request for Information (RFI): Inviting
Comments and Suggestions on an
ODS Strategic Plan 2025–2029: A
Blueprint for a Coordinated Dietary
Supplement Research Agenda at NIH
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Request for information.
The National Institutes of
Health (NIH), Office of Dietary
Supplements (ODS) is continuing to use
a structured planning process to
develop its five-year strategic plans.
After a new director joined ODS in July
2023 a new strategic plan for 2025–2029
was developed titled ‘‘A Blueprint for a
Coordinated Dietary Supplement
Research Agenda at NIH.’’ ODS is
committed to engaging its partners and
other interested parties including
representatives of the scientific
community, industry, other federal
agencies, policymakers, and the public
in the strategic planning process by
soliciting their comments on the draft
ODS Strategic Plan for Fiscal Years (CY)
2025–2029.
DATES: The RFI is open for public
comment for a period of 60 days. To
ensure consideration, comments must
be submitted by August 30, 2024.
ADDRESSES: All comments must be
submitted electronically to ODSplan@
od.nih.gov. You will receive an
electronic confirmation acknowledging
receipt of your response.
FOR FURTHER INFORMATION CONTACT:
Barbara Cohen, Ph.D., at ODSplan@
od.nih.gov or (301) 435–2920.
SUPPLEMENTARY INFORMATION: This
notice is in accordance with the 21st
Century Cures Act, wherein NIH
institutes are required to regularly
update their strategic plans. The
purpose of the CY 2025–2029 ODS
Strategic Plan (https://ods.od.nih.gov/
SUMMARY:
E:\FR\FM\01JYN1.SGM
01JYN1
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 126 / Monday, July 1, 2024 / Notices
About/StrategicPlan.aspx) is to
communicate how ODS will advance its
mission to coordinate cutting-edge
dietary supplement research across NIH
Institutes, Centers, and Offices (ICOs)
and other federal agencies to foster
knowledge and optimize health across
the lifespan. The plan articulates ODS’
priorities as follows:
• To coordinate and support dietary
supplement research focused on
biological, population, and product
sciences.
• To develop NIH dietary supplement
initiatives that incorporate rigorous
dietary supplement research methods
and make best use of available NIH
funding mechanisms.
• To support ODS programs and
develop and disseminate dietary
supplement research findings and
research resources to ODS audiences.
ODS has completed a draft of its FiveYear Strategic Plan for CY 2025–2029
(https://ods.od.nih.gov/About/
StrategicPlan.aspx) and is interested in
receiving feedback from all interested
parties on the following:
• Any additional emerging public
health issues or knowledge gaps that
ODS can help address.
• Partnerships NIH should pursue,
both inside and outside of government,
to advance research on dietary
supplements.
ODS encourages organizations to
submit a single response reflective of
the views of the organization as a whole.
Responses to this RFI are voluntary
and may be submitted anonymously.
Please do not include any personally
identifiable information or any
information that you do not wish to
make public. Proprietary, classified,
confidential, or sensitive information
should not be included in your
response. NIH will use the information
submitted in response to this Request
for Information (RFI) at its discretion.
NIH reserves the right to use any
submitted information on public
websites, in reports, in summaries of the
state of the science, in any possible
resultant solicitation(s), grant(s), or
cooperative agreement(s), or in the
development of future funding
opportunity announcements. This RFI is
for informational and planning purposes
only and is not a solicitation for
applications or an obligation on the part
of the Government to provide support
for any ideas identified in response to
it. Please note that the Government will
not pay for the preparation of any
information submitted or for the use of
that information.
No basis for claims against the U.S.
Government shall arise as a result of a
response to this RFI or from the
VerDate Sep<11>2014
20:36 Jun 28, 2024
Jkt 262001
Government’s use of such information.
Additionally, the Government cannot
guarantee the confidentiality of the
information provided.
Dated: June 20, 2024.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
[FR Doc. 2024–14481 Filed 6–28–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–23–
110: Biomedical Technology Optimization
and Dissemination Center (BTOD).
Date: July 24, 2024.
Time: 9:00 a.m. to 7:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Jingwu Xie, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 594–8625, jingwu.xie@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Topics in Disease Control and
Applied Immunology.
Date: July 29, 2024.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Emily Foley, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 402–3016, emily.foley@nih.gov.
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
54473
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cardiovascular and Vascular
Sciences.
Date: July 30, 2024.
Time: 9:00 a.m. to 9:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Courtney Elaine Watkins,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 496–3093, courtney.watkins2@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Topics on HIV Virology,
Immunopathogenesis, Drug and Vaccine
Development.
Date: July 31, 2024.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Kumud Singh, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 761–7830, kumud.singh@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Physiology and Pathobiology of
Cardiovascular and Respiratory Systems.
Date: July 31–August 1, 2024.
Time: 10:00 a.m. to 9:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Heidi B Friedman, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 907–H,
Bethesda, MD 20892, (301) 379–5632,
hfriedman@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: HIV/AIDS Behavioral Panel.
Date: August 2, 2024.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Mark P Rubert, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218,
MSC 7852, Bethesda, MD 20892, 301–806–
6596, rubertm@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
E:\FR\FM\01JYN1.SGM
01JYN1
Agencies
[Federal Register Volume 89, Number 126 (Monday, July 1, 2024)]
[Notices]
[Pages 54472-54473]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-14481]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Request for Information (RFI): Inviting Comments and Suggestions
on an ODS Strategic Plan 2025-2029: A Blueprint for a Coordinated
Dietary Supplement Research Agenda at NIH
AGENCY: National Institutes of Health, HHS.
ACTION: Request for information.
-----------------------------------------------------------------------
SUMMARY: The National Institutes of Health (NIH), Office of Dietary
Supplements (ODS) is continuing to use a structured planning process to
develop its five-year strategic plans. After a new director joined ODS
in July 2023 a new strategic plan for 2025-2029 was developed titled
``A Blueprint for a Coordinated Dietary Supplement Research Agenda at
NIH.'' ODS is committed to engaging its partners and other interested
parties including representatives of the scientific community,
industry, other federal agencies, policymakers, and the public in the
strategic planning process by soliciting their comments on the draft
ODS Strategic Plan for Fiscal Years (CY) 2025-2029.
DATES: The RFI is open for public comment for a period of 60 days. To
ensure consideration, comments must be submitted by August 30, 2024.
ADDRESSES: All comments must be submitted electronically to
[email protected]. You will receive an electronic confirmation
acknowledging receipt of your response.
FOR FURTHER INFORMATION CONTACT: Barbara Cohen, Ph.D., at
[email protected] or (301) 435-2920.
SUPPLEMENTARY INFORMATION: This notice is in accordance with the 21st
Century Cures Act, wherein NIH institutes are required to regularly
update their strategic plans. The purpose of the CY 2025-2029 ODS
Strategic Plan (https://ods.od.nih.gov/
[[Page 54473]]
About/StrategicPlan.aspx) is to communicate how ODS will advance its
mission to coordinate cutting-edge dietary supplement research across
NIH Institutes, Centers, and Offices (ICOs) and other federal agencies
to foster knowledge and optimize health across the lifespan. The plan
articulates ODS' priorities as follows:
To coordinate and support dietary supplement research
focused on biological, population, and product sciences.
To develop NIH dietary supplement initiatives that
incorporate rigorous dietary supplement research methods and make best
use of available NIH funding mechanisms.
To support ODS programs and develop and disseminate
dietary supplement research findings and research resources to ODS
audiences.
ODS has completed a draft of its Five-Year Strategic Plan for CY
2025-2029 (https://ods.od.nih.gov/About/StrategicPlan.aspx) and is
interested in receiving feedback from all interested parties on the
following:
Any additional emerging public health issues or knowledge
gaps that ODS can help address.
Partnerships NIH should pursue, both inside and outside of
government, to advance research on dietary supplements.
ODS encourages organizations to submit a single response reflective
of the views of the organization as a whole.
Responses to this RFI are voluntary and may be submitted
anonymously. Please do not include any personally identifiable
information or any information that you do not wish to make public.
Proprietary, classified, confidential, or sensitive information should
not be included in your response. NIH will use the information
submitted in response to this Request for Information (RFI) at its
discretion. NIH reserves the right to use any submitted information on
public websites, in reports, in summaries of the state of the science,
in any possible resultant solicitation(s), grant(s), or cooperative
agreement(s), or in the development of future funding opportunity
announcements. This RFI is for informational and planning purposes only
and is not a solicitation for applications or an obligation on the part
of the Government to provide support for any ideas identified in
response to it. Please note that the Government will not pay for the
preparation of any information submitted or for the use of that
information.
No basis for claims against the U.S. Government shall arise as a
result of a response to this RFI or from the Government's use of such
information. Additionally, the Government cannot guarantee the
confidentiality of the information provided.
Dated: June 20, 2024.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes of Health.
[FR Doc. 2024-14481 Filed 6-28-24; 8:45 am]
BILLING CODE 4140-01-P